Investigation of Prolactin Receptor Activation and Blockade Using Time-Resolved Fluorescence Resonance Energy Transfer

The prolactin receptor (PRLR) is emerging as a therapeutic target in oncology. Knowledge-based drug design led to the development of a pure PRLR antagonist (Del1-9-G129R-hPRL) that was recently shown to prevent PRL-induced mouse prostate tumorogenesis. In humans, the first gain-of-function mutation...

Full description

Bibliographic Details
Main Authors: Estelle eTallet, Isabelle eFernandez, Chi eZhang, Marion eSalsac, Nathalie eGregor, Mohammed Akli Ayoub, Jean-Philippe ePin, Eric eTrinquet, Vincent eGoffin
Format: Article
Language:English
Published: Frontiers Media S.A. 2011-09-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fendo.2011.00029/full